Lin SN - Search Results

1

Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Lin SN, Mao R, Qian C, Bettenworth D, Wang J, Li J, Bruining DH, Jairath V, Feagan BG, Chen MH; Stenosis Therapy and Antifibrotic Research (STAR) Consortium; Rieder F. Lin SN, et al. Physiol Rev. 2022 Apr 1;102(2):605-652. doi: 10.1152/physrev.00005.2021. Epub 2021 Sep 27. Physiol Rev. 2022. PMID: 34569264 Free PMC article. Review.

2

A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn's Disease in Chinese Patients.

Lin S, Wang Y, Li L, Chen P, Mao R, Feng R, Qiu Y, He Y, Chen B, Zeng Z, Chen M, Zhang S. Lin S, et al. Mediators Inflamm. 2018 Dec 16;2018:3275025. doi: 10.1155/2018/3275025. eCollection 2018. Mediators Inflamm. 2018. PMID: 30647532 Free PMC article.

3

Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease.

Huang S, Li L, Ben-Horin S, Mao R, Lin S, Qiu Y, Feng R, He Y, Chen B, Zeng Z, Chen M, Zhang S. Huang S, et al. Clin Transl Gastroenterol. 2019 Mar;10(3):e00015. doi: 10.14309/ctg.0000000000000015. Clin Transl Gastroenterol. 2019. PMID: 30839440 Free PMC article.

4

Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment.

Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Feng T, et al. Inflamm Bowel Dis. 2019 Oct 18;25(11):1813-1821. doi: 10.1093/ibd/izz061. Inflamm Bowel Dis. 2019. PMID: 30934050

5

Pathogenesis of fibrostenosing Crohn's disease.

Li J, Mao R, Kurada S, Wang J, Lin S, Chandra J, Rieder F. Li J, et al. Transl Res. 2019 Jul;209:39-54. doi: 10.1016/j.trsl.2019.03.005. Epub 2019 Mar 26. Transl Res. 2019. PMID: 30981697 Review.

6

Making Qualitative Intestinal Stricture Quantitative: Embracing Radiomics in IBD.

Lin S, Lin X, Li X, Chen M, Mao R. Lin S, et al. Inflamm Bowel Dis. 2020 Apr 11;26(5):743-745. doi: 10.1093/ibd/izz197. Inflamm Bowel Dis. 2020. PMID: 31504502 No abstract available.

7

Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?

He JS, Tan JY, Li XZ, Feng R, Xiong SS, Lin SN, Qiu Y, Mao R. He JS, et al. Among authors: lin sn. J Dig Dis. 2020 Jun;21(6):336-341. doi: 10.1111/1751-2980.12913. J Dig Dis. 2020. PMID: 32496631 Review.

8

Gastrointestinal and liver involvement in patients with COVID-19 - Authors' reply.

Qiu Y, He JS, Tan JY, Lin SN, Mao R. Qiu Y, et al. Among authors: lin sn. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):799-800. doi: 10.1016/S2468-1253(20)30240-5. Lancet Gastroenterol Hepatol. 2020. PMID: 32818457 Free PMC article. No abstract available.

9

Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.

Zhou LY, Lin SN, Rieder F, Chen MH, Zhang SH, Mao R. Zhou LY, et al. Among authors: lin sn. Inflamm Bowel Dis. 2021 Jun 15;27(7):971-982. doi: 10.1093/ibd/izaa321. Inflamm Bowel Dis. 2021. PMID: 33324986 Free PMC article. Review.

10

Classifying Crohn's disease into colon-involving versus non-colon-involving groups is a better predictor of clinical outcomes than the Montreal classification.

Lin SN, Zheng DP, Qiu Y, Zhang SH, He Y, Chen BL, Zeng ZR, Mao R, Chen MH. Lin SN, et al. Therap Adv Gastroenterol. 2020 Dec 3;13:1756284820968732. doi: 10.1177/1756284820968732. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 33329758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters